Cargando…
Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia
In recent years, one of the most successful advances in treating acute myeloid leukaemia (AML) has been the combination of the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax with hypomethylating agents (decitabine or azacytidine). This combination treatment has an accelerated approval by the Food an...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404627/ https://www.ncbi.nlm.nih.gov/pubmed/34471510 http://dx.doi.org/10.1177/20406207211040335 |
_version_ | 1783746204831580160 |
---|---|
author | Báez-Gutiérrez, Nerea Rodríguez-Ramallo, Héctor Moreno, María Antonia-Pérez Arboli, Eduardo-Rodriguez Abdel-kader Martín, Laila |
author_facet | Báez-Gutiérrez, Nerea Rodríguez-Ramallo, Héctor Moreno, María Antonia-Pérez Arboli, Eduardo-Rodriguez Abdel-kader Martín, Laila |
author_sort | Báez-Gutiérrez, Nerea |
collection | PubMed |
description | In recent years, one of the most successful advances in treating acute myeloid leukaemia (AML) has been the combination of the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax with hypomethylating agents (decitabine or azacytidine). This combination treatment has an accelerated approval by the Food and Drug Administration for newly diagnosed AML adults who are 75 years of age or older or who have comorbidities and are not eligible to receive intensive induction chemotherapy. AML is the most common form of acute leukaemia in adults, with a median age at diagnosis of 68 years. Consequently, most of the patients included in the studies are elderly. Traditionally, young patients achieve higher remission rates compared with the elderly AML population. Although venetoclax combination therapy could become a treatment option for treating young patients with relapsed/refractory AML, this regimen has not been systematically tested in this setting. In this study, we summarize the currently available evidence on the treatment of venetoclax in combination with hypomethylating agents for the treatment of young relapsed/refractory AML patients, in addition to our experience in clinical practice with two case reports. Venetoclax, combined with hypomethylating agents, seems to be an effective option for young relapsed/refractory AML patients. However, due to the poor quality of the evidence, additional well-designed studies with greater numbers of patients are needed to confirm the effectiveness and safety of venetoclax combination regimens for this population. |
format | Online Article Text |
id | pubmed-8404627 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-84046272021-08-31 Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia Báez-Gutiérrez, Nerea Rodríguez-Ramallo, Héctor Moreno, María Antonia-Pérez Arboli, Eduardo-Rodriguez Abdel-kader Martín, Laila Ther Adv Hematol Case Series In recent years, one of the most successful advances in treating acute myeloid leukaemia (AML) has been the combination of the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax with hypomethylating agents (decitabine or azacytidine). This combination treatment has an accelerated approval by the Food and Drug Administration for newly diagnosed AML adults who are 75 years of age or older or who have comorbidities and are not eligible to receive intensive induction chemotherapy. AML is the most common form of acute leukaemia in adults, with a median age at diagnosis of 68 years. Consequently, most of the patients included in the studies are elderly. Traditionally, young patients achieve higher remission rates compared with the elderly AML population. Although venetoclax combination therapy could become a treatment option for treating young patients with relapsed/refractory AML, this regimen has not been systematically tested in this setting. In this study, we summarize the currently available evidence on the treatment of venetoclax in combination with hypomethylating agents for the treatment of young relapsed/refractory AML patients, in addition to our experience in clinical practice with two case reports. Venetoclax, combined with hypomethylating agents, seems to be an effective option for young relapsed/refractory AML patients. However, due to the poor quality of the evidence, additional well-designed studies with greater numbers of patients are needed to confirm the effectiveness and safety of venetoclax combination regimens for this population. SAGE Publications 2021-08-28 /pmc/articles/PMC8404627/ /pubmed/34471510 http://dx.doi.org/10.1177/20406207211040335 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Case Series Báez-Gutiérrez, Nerea Rodríguez-Ramallo, Héctor Moreno, María Antonia-Pérez Arboli, Eduardo-Rodriguez Abdel-kader Martín, Laila Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia |
title | Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia |
title_full | Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia |
title_fullStr | Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia |
title_full_unstemmed | Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia |
title_short | Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia |
title_sort | venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia |
topic | Case Series |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404627/ https://www.ncbi.nlm.nih.gov/pubmed/34471510 http://dx.doi.org/10.1177/20406207211040335 |
work_keys_str_mv | AT baezgutierreznerea venetoclaxcombinationtherapywithhypomethylatingagentsinyoungadultswithrelapsedrefractoryacutemyeloidleukaemia AT rodriguezramallohector venetoclaxcombinationtherapywithhypomethylatingagentsinyoungadultswithrelapsedrefractoryacutemyeloidleukaemia AT morenomariaantoniaperez venetoclaxcombinationtherapywithhypomethylatingagentsinyoungadultswithrelapsedrefractoryacutemyeloidleukaemia AT arbolieduardorodriguez venetoclaxcombinationtherapywithhypomethylatingagentsinyoungadultswithrelapsedrefractoryacutemyeloidleukaemia AT abdelkadermartinlaila venetoclaxcombinationtherapywithhypomethylatingagentsinyoungadultswithrelapsedrefractoryacutemyeloidleukaemia |